Preparação de compósitos híbridos para aplicação como carreadores de fármaco no tratamento da osteomielite.

Abstract

In this research, we propose, obtain and characterize in an unprecedented way hybrid compounds (new drug carriers) the base on hydroxyapatite and nanoparticles associated with tetraethylorthosilicate (TEOS) and the silane agent type 3- aminopropyltrimethoxysilane (APTS) conjugated to the drug ciproflonax and evaluate the effect of treatment osteomyelitis. In a first step, the individual materials synthesized were. In the second stage, hybrids and hybrid composites obtained were in different concentrations. The precursor materials and carriers obtained in steps I and II characterized were by structural, morphological and magnetic analysis techniques aiming at understanding the properties in the formation of the drug delivery. The results of steps I and II indicated that the Fe3O4 magnetic nanoparticles (NPM’s) were successfully obtained by microwave oven and CoFe2O4 combustion reaction in a pilot scale scale reaction; The monophasic hydroxyapatite (HAp) obtained by the precipitation method and NPM's@SiO2 hybrids (core-shell). In step II the hybrid composites (magnetic drug delivery) were the base of the hybrid NPMs and the commercial HAp of JHS Biomaterials and synthesized in the laboratory, with crystalline and nanostructural characteristics. In that both the precursors obtained in step I and the hybrid composites showed promising structural, morphological and magnetic properties for use as a drug delivery specifically in the treatment of osteomyelitis. In stage III the in vitro cytotoxicity assays were performed for the hybrid precursors and composites obtained and drug release tests for the hybrid composites (carriers). The Fe3O4, CoFe2O4 NPM’s of the Fe3O4@SiO2 and CoFe2O4 @SiO2 hybrids and the hydroxyapatite (HAp) synthesized in LaBSmaC were shown to have cell viability greater than 70% and that the NPM’s coating of Fe3O4, CoFe2O4 and hybrid uptake have further increased cell viability and biocompatibility of magnetic NPM’s as carriers of the drug ciprofloxacin. The biocompatibility of the hybrid composites (drug delivery) and of the PVA solvent used for carrier dispersion evaluated were at various concentrations via in vitro (cytotoxicity) studies. It observed was by the cytotoxic profile that the safe concentration, in which the cell viability was higher than 70%, was 0.312 mg/mL for the hybrid composites (carriers) HFeFS1, HFeFS2, HCoFS1, HJCoFS1, F, e de 0,156 mg/mL para o compósito HCoFS1.composite. Drug release tests, for the hybrid (carrier) composites confirmed that, both Fe3O4@SiO2 and CoFe2O4@SiO2 carriers presented high efficiency in the conjugation and release of the drug ciprofloxacin. However, the hybrid composites synthesized with CoFe2O4 and the commercial HAp from JHS Biomaterials, presented faster release when compared to hybrid composites formed with Fe3O4 and HAp synthesized in the laboratory. All these characteristics allowed helping in the understanding of the properties of the studied materials for that these are optimized efficiently for the development of a technological product, efficient for application in the treatment of osteomyelitis.